Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.538 EUR
308.37 M EUR
3.00 B EUR
332.30 M
About ONO Pharmaceutical Co., Ltd.
Sector
Industry
CEO
Gyo Sagara
Website
Headquarters
Osaka
Founded
1717
ISIN
JP3197600004
FIGI
BBG000C4Q9Y2
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange ONO Pharmaceutical Co., Ltd. stocks are traded under the ticker ON4.
We've gathered analysts' opinions on ONO Pharmaceutical Co., Ltd. future price: according to them, ON4 price has a max estimate of 10.14 EUR and a min estimate of 7.32 EUR. Watch ON4 chart and read a more detailed ONO Pharmaceutical Co., Ltd. stock forecast: see what analysts think of ONO Pharmaceutical Co., Ltd. and suggest that you do with its stocks.
Yes, you can track ONO Pharmaceutical Co., Ltd. financials in yearly and quarterly reports right on TradingView.
ONO Pharmaceutical Co., Ltd. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
ON4 earnings for the last quarter are 0.22 EUR per share, whereas the estimation was 0.29 EUR resulting in a −23.95% surprise. The estimated earnings for the next quarter are 0.23 EUR per share. See more details about ONO Pharmaceutical Co., Ltd. earnings.
ONO Pharmaceutical Co., Ltd. revenue for the last quarter amounts to 751.26 M EUR, despite the estimated figure of 702.29 M EUR. In the next quarter, revenue is expected to reach 703.53 M EUR.
ON4 net income for the last quarter is 103.61 M EUR, while the quarter before that showed −40.33 M EUR of net income which accounts for 356.91% change. Track more ONO Pharmaceutical Co., Ltd. financial stats to get the full picture.
ONO Pharmaceutical Co., Ltd. dividend yield was 4.99% in 2024, and payout ratio reached 75.08%. The year before the numbers were 3.26% and 30.01% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 19, 2025, the company has 4.29 K employees. See our rating of the largest employees — is ONO Pharmaceutical Co., Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ONO Pharmaceutical Co., Ltd. EBITDA is 512.84 M EUR, and current EBITDA margin is 18.54%. See more stats in ONO Pharmaceutical Co., Ltd. financial statements.
Like other stocks, ON4 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONO Pharmaceutical Co., Ltd. stock right from TradingView charts — choose your broker and connect to your account.